当前位置: 首页 >> 检索结果
1082. Chief cell plasticity is the origin of metaplasia following acute injury in the stomach mucosa.
作者: Brianna Caldwell.;Anne R Meyer.;Jared A Weis.;Amy C Engevik.;Eunyoung Choi.
来源: Gut. 2022年71卷6期1068-1077页
Metaplasia arises from differentiated cell types in response to injury and is considered a precursor in many cancers. Heterogeneous cell lineages are present in the reparative metaplastic mucosa with response to injury, including foveolar cells, proliferating cells and spasmolytic polypeptide-expressing metaplasia (SPEM) cells, a key metaplastic cell population. Zymogen-secreting chief cells are long-lived cells in the stomach mucosa and have been considered the origin of SPEM cells; however, a conflicting paradigm has proposed isthmal progenitor cells as an origin for SPEM.
1083. Patients with mesenchymal tumours and high Fusobacteriales prevalence have worse prognosis in colorectal cancer (CRC).
作者: Manuela Salvucci.;Nyree Crawford.;Katie Stott.;Susan Bullman.;Daniel B Longley.;Jochen H M Prehn.
来源: Gut. 2022年71卷8期1600-1612页
Transcriptomic-based subtyping, consensus molecular subtyping (CMS) and colorectal cancer intrinsic subtyping (CRIS) identify a patient subpopulation with mesenchymal traits (CMS4/CRIS-B) and poorer outcome. Here, we investigated the relationship between prevalence of Fusobacterium nucleatum (Fn) and Fusobacteriales, CMS/CRIS subtyping, cell type composition, immune infiltrates and host contexture to refine patient stratification and to identify druggable context-specific vulnerabilities.
1084. Discontinuation of nucleot(s)ide analogue therapy in HBeAg-negative chronic hepatitis B: a meta-analysis.
作者: Samuel Anthony Lachlan Hall.;Sara Vogrin.;Olivia Wawryk.;Gareth S Burns.;Kumar Visvanathan.;Vijaya Sundararajan.;Alexander Thompson.
来源: Gut. 2022年71卷8期1629-1641页
Sustained virological suppression and hepatitis B surface antigen (HBsAg) loss have been described after nucleot(s)ide analogue (NA) discontinuation for patients with hepatitis B e antigen (HBeAg)-negative chronic hepatitis B (CHB). We performed a meta-analysis of the clinical outcomes after NA discontinuation for HBeAg-negative CHB.
1085. Integrated prognostic and histogenomic justification of stage-directed therapy for single large hepatocellular carcinoma: a Korean nationwide registry study.
作者: Jihyun An.;Ha Il Kim.;Bora Oh.;Yoo-Jin Oh.;Ji-Hye Oh.;Wonkyung Kim.;Chang Ohk Sung.;Ju Hyun Shim.
来源: Gut. 2022年71卷6期1234-1236页 1086. Genomic temporal heterogeneity of circulating tumour DNA in unresectable metastatic colorectal cancer under first-line treatment.
作者: Feng Wang.;You-Sheng Huang.;Hao-Xiang Wu.;Zi-Xian Wang.;Ying Jin.;Yi-Chen Yao.;Yan-Xing Chen.;Qi Zhao.;Shifu Chen.;Ming-Ming He.;Hui-Yan Luo.;Miao-Zhen Qiu.;De-Shen Wang.;Feng-Hua Wang.;Mingyan Xu.;Yu-Hong Li.;Rui-Hua Xu.
来源: Gut. 2022年71卷7期1340-1349页
Circulating tumour DNA (ctDNA) sequencing is increasingly used in the clinical management of patients with colorectal cancer. However, the genomic heterogeneity in ctDNA during treatments and its impact on clinical outcomes remain largely unknown.
1087. STAT3-mediated upregulation of the AIM2 DNA sensor links innate immunity with cell migration to promote epithelial tumourigenesis.
作者: Ruby E Dawson.;Virginie Deswaerte.;Alison C West.;Ke Tang.;Alice J West.;Jesse J Balic.;Linden J Gearing.;Mohamed I Saad.;Liang Yu.;Yonghui Wu.;Prithi S Bhathal.;Beena Kumar.;Jayati T Chakrabarti.;Yana Zavros.;Hiroko Oshima.;Dennis M Klinman.;Masanobu Oshima.;Patrick Tan.;Brendan J Jenkins.
来源: Gut. 2022年71卷8期1515-1531页
The absent in melanoma 2 (AIM2) cytosolic pattern recognition receptor and DNA sensor promotes the pathogenesis of autoimmune and chronic inflammatory diseases via caspase-1-containing inflammasome complexes. However, the role of AIM2 in cancer is ill-defined.
1088. Non-alcoholic fatty liver disease and incident major adverse cardiovascular events: results from a nationwide histology cohort.
作者: Tracey G Simon.;Bjorn Roelstraete.;Hannes Hagström.;Johan Sundström.;Jonas F Ludvigsson.
来源: Gut. 2022年71卷9期1867-1875页
Some data suggest a positive association between non-alcoholic fatty liver disease (NAFLD) and incident major adverse cardiovascular events (MACEs). However, data are lacking from large cohorts with liver histology, which remains the gold standard for staging NAFLD severity.
1090. Residual homing of α4β7-expressing β1+PI16+ regulatory T cells with potent suppressive activity correlates with exposure-efficacy of vedolizumab.
作者: Emily Becker.;Mark Dedden.;Christine Gall.;Maximilian Wiendl.;Arif Bülent Ekici.;Anja Schulz-Kuhnt.;Anna Schweda.;Caroline Voskens.;Ahmed Hegazy.;Francesco Vitali.;Raja Atreya.;Tanja Martina Müller.;Imke Atreya.;Markus F Neurath.;Sebastian Zundler.
来源: Gut. 2022年71卷8期1551-1566页
The anti-α4β7 integrin antibody vedolizumab is administered at a fixed dose for the treatment of IBDs. This leads to a wide range of serum concentrations in patients and previous studies had suggested that highest exposure levels are associated with suboptimal clinical response. We aimed to determine the mechanisms underlying these non-linear exposure-efficacy characteristics of vedolizumab.
1091. Integrated analysis of the faecal metagenome and serum metabolome reveals the role of gut microbiome-associated metabolites in the detection of colorectal cancer and adenoma.
作者: Feng Chen.;Xudong Dai.;Chang-Chun Zhou.;Ke-Xin Li.;Yu-Juan Zhang.;Xiao-Ying Lou.;Yuan-Min Zhu.;Yan-Lai Sun.;Bao-Xiang Peng.;Wei Cui.
来源: Gut. 2022年71卷7期1315-1325页
To profile gut microbiome-associated metabolites in serum and investigate whether these metabolites could distinguish individuals with colorectal cancer (CRC) or adenoma from normal healthy individuals.
1092. Epigenetic promoter alterations in GI tumour immune-editing and resistance to immune checkpoint inhibition.
作者: Raghav Sundar.;Kie-Kyon Huang.;Vikrant Kumar.;Kalpana Ramnarayanan.;Deniz Demircioglu.;Zhisheng Her.;Xuewen Ong.;Zul Fazreen Bin Adam Isa.;Manjie Xing.;Angie Lay-Keng Tan.;David Wai Meng Tai.;Su Pin Choo.;Weiwei Zhai.;Jia Qi Lim.;Meghna Das Thakur.;Luciana Molinero.;Edward Cha.;Marcella Fasso.;Monica Niger.;Filippo Pietrantonio.;Jeeyun Lee.;Anand D Jeyasekharan.;Aditi Qamra.;Radhika Patnala.;Arne Fabritius.;Mark De Simone.;Joe Yeong.;Cedric Chuan Young Ng.;Sun Young Rha.;Yukiya Narita.;Kei Muro.;Yu Amanda Guo.;Anders Jacobsen Skanderup.;Jimmy Bok Yan So.;Wei Peng Yong.;Qingfeng Chen.;Jonathan Göke.;Patrick Tan.
来源: Gut. 2022年71卷7期1277-1288页
Epigenomic alterations in cancer interact with the immune microenvironment to dictate tumour evolution and therapeutic response. We aimed to study the regulation of the tumour immune microenvironment through epigenetic alternate promoter use in gastric cancer and to expand our findings to other gastrointestinal tumours.
1093. Maternal obesity, pregnancy weight gain, and birth weight and risk of colorectal cancer.
作者: Caitlin C Murphy.;Piera M Cirillo.;Nickilou Y Krigbaum.;Amit G Singal.;MinJae Lee.;Timothy Zaki.;Ezra Burstein.;Barbara A Cohn.
来源: Gut. 2022年71卷7期1332-1339页
Colorectal cancer (CRC) is a leading cause of cancer-related death worldwide. Obesity is a well-established risk factor for CRC, and fetal or developmental origins of obesity may underlie its effect on cancer in adulthood. We examined associations of maternal obesity, pregnancy weight gain, and birth weight and CRC in adult offspring.
1094. GM-CSF drives myelopoiesis, recruitment and polarisation of tumour-associated macrophages in cholangiocarcinoma and systemic blockade facilitates antitumour immunity.
作者: Luis I Ruffolo.;Katherine M Jackson.;Peyton C Kuhlers.;Benjamin S Dale.;Nathania M Figueroa Guilliani.;Nicholas A Ullman.;Paul R Burchard.;Shuyang S Qin.;Peter G Juviler.;Jessica Millian Keilson.;Ashley B Morrison.;Mary Georger.;Rachel Jewell.;Laura M Calvi.;Timothy M Nywening.;Michael R O'Dell.;Aram F Hezel.;Luis De Las Casas.;Gregory B Lesinski.;Jen Jen Yeh.;Roberto Hernandez-Alejandro.;Brian A Belt.;David C Linehan.
来源: Gut. 2022年71卷7期1386-1398页
Intrahepatic cholangiocarcinoma (iCCA) is rising in incidence, and at present, there are limited effective systemic therapies. iCCA tumours are infiltrated by stromal cells, with high prevalence of suppressive myeloid populations including tumour-associated macrophages (TAMs) and myeloid-derived suppressor cells (MDSCs). Here, we show that tumour-derived granulocyte-macrophage colony-stimulating factor (GM-CSF) and the host bone marrow is central for monopoiesis and potentiation of TAMs, and abrogation of this signalling axis facilitates antitumour immunity in a novel model of iCCA.
1095. Human gastric microbiota transplantation recapitulates premalignant lesions in germ-free mice.
作者: Soon-Kyeong Kwon.;Jun Chul Park.;Kwang H Kim.;Jaekyung Yoon.;Yejin Cho.;Buhyun Lee.;Jin-Jae Lee.;Haengdueng Jeong.;Yeseul Oh.;Sung-Hee Kim.;So Dam Lee.;Bo Ram Hwang.;Yusook Chung.;Jihyun F Kim.;Ki Taek Nam.;Yong Chan Lee.
来源: Gut. 2022年71卷7期1266-1276页
Gastric cancer (GC) is a leading cause of cancer-related mortality. Although microbes besides Helicobacter pylori may also contribute to gastric carcinogenesis, wild-type germ-free (GF) mouse models investigating the role of human gastric microbiota in the process are not yet available. We aimed to evaluate the histopathological features of GF mouse stomachs transplanted with gastric microbiota from patients with different gastric disease states and their relationships with the microbiota.
1096. Comparison between non-pulmonary and pulmonary immune responses in a HIV decedent who succumbed to COVID-19.
作者: Denise Goh.;Justina Nadia Lee.;Tracy Tien.;Jeffrey Chun Tatt Lim.;Sherlly Lim.;An Sen Tan.;Jin Liu.;Benedict Tan.;Joe Yeong.
来源: Gut. 2022年71卷6期1231-1234页 1097. Application of Lyon Consensus criteria for GORD diagnosis: evaluation of conventional and new impedance-pH parameters.
作者: Leonardo Frazzoni.;Marzio Frazzoni.;Nicola De Bortoli.;Mentore Ribolsi.;Salvatore Tolone.;Salvatore Russo.;Rita Luisa Conigliaro.;Roberto Penagini.;Lorenzo Fuccio.;Rocco Maurizio Zagari.;Edoardo Savarino.
来源: Gut. 2022年71卷6期1062-1067页
To validate Lyon Consensus criteria for diagnosing gastro-oesophageal reflux disease (GORD) by reflux monitoring.
1099. Efficacy of a low FODMAP diet in irritable bowel syndrome: systematic review and network meta-analysis.
A diet low in fermentable oligosaccharides, disaccharides, monosaccharides, and polyols (FODMAP) is recommended for irritable bowel syndrome (IBS), if general lifestyle and dietary advice fails. However, although the impact of a low FODMAP diet on individual IBS symptoms has been examined in some randomised controlled trials (RCTs), there has been no recent systematic assessment, and individual trials have studied numerous alternative or control interventions, meaning the best comparator is unclear. We performed a network meta-analysis addressing these uncertainties.
1100. Psyllium reduces inulin-induced colonic gas production in IBS: MRI and in vitro fermentation studies.
作者: David Gunn.;Zainab Abbas.;Hannah C Harris.;Giles Major.;Caroline Hoad.;Penny Gowland.;Luca Marciani.;Samantha K Gill.;Fred J Warren.;Megan Rossi.;Jose Maria Remes-Troche.;Kevin Whelan.;Robin C Spiller.
来源: Gut. 2022年71卷5期919-927页
Health-promoting dietary fibre including inulin often triggers gastrointestinal symptoms in patients with IBS, limiting their intake. Our aim was to test if coadministering psyllium with inulin would reduce gas production.
|